04.28.15
Bristol-Myers Squibb
1Q Revenues: $4.0 billion (+4%)
1Q Earnings: $1.2 billion (+27%)
Comments: U.S. revenues were up 16% to $2.0 billion in the quarter. International revenues decreased 2% to $2.0 billion. Eliquis sales were $355 million, up from $106 million in 1Q14. Yervoy sales were up 20% to $325 million. Orencia and Sprycel grew 10% to $400 million and $375 million, respectively. Daklinza and Sunvepra had combined sales of $264 million and Opdivo had sales of $40 million. R&D expenses were up 7% to $1.0 billion in the quarter.
1Q Revenues: $4.0 billion (+4%)
1Q Earnings: $1.2 billion (+27%)
Comments: U.S. revenues were up 16% to $2.0 billion in the quarter. International revenues decreased 2% to $2.0 billion. Eliquis sales were $355 million, up from $106 million in 1Q14. Yervoy sales were up 20% to $325 million. Orencia and Sprycel grew 10% to $400 million and $375 million, respectively. Daklinza and Sunvepra had combined sales of $264 million and Opdivo had sales of $40 million. R&D expenses were up 7% to $1.0 billion in the quarter.